Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalPain ManagementAnesthesiaTrial Update

Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction

Positive results could lead to a shift in clinical guidelines favoring SPSIPB, affecting market dynamics for anesthetic techniques and opioid alternatives.

Published: June 2, 2026
Updated: June 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / Anesthesia
Company: Pain Management
Asset: Anesthesia
Trial SummaryCLN

Phase III

Pain Management / Anesthesia

Status

Active

Sponsor

Pain Management

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Strategic implication

Positive results could lead to a shift in clinical guidelines favoring SPSIPB, affecting market dynamics for anesthetic techniques and opioid alternatives.

Why it matters

Positive results could lead to a shift in clinical guidelines favoring SPSIPB, affecting market dynamics for anesthetic techniques and opioid alternatives.

What changed

Trial Update

Analysis

This clinical trial aims to compare the analgesic efficacy of Serratus Posterior Superior Intercostal Plane Block and Thoracic Paravertebral Block in reducing postoperative opioid consumption after open thoracotomy.

Positive results could lead to a shift in clinical guidelines favoring SPSIPB, affecting market dynamics for anesthetic techniques and opioid alternatives.

Monitor the trial results for differences in opioid consumption and respiratory outcomes, as well as subsequent adoption in clinical practice.

Related companies & assets

Companies

  • View signals for Pain Management →
  • View signals for Trial Update →

Assets

  • Anesthesia →

Sources & Humanexa intelligence

Source links

  • Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction ↗

Related Humanexa pages

  • Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction →

Related signals

Trial SummaryCLN

Phase III

Oncology / Breast Cancer

Status

Active

Sponsor

Roche

Signal Score

8.2

Clinicalhigh signal

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

June 18, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / BRAF/MEK Inhibitors

Status

Initiated

Sponsor

Novartis

Signal Score

8.2

Clinicalhigh signal

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

June 18, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.